Ultragenyx Pharmaceutical Inc.
RARE
$21.34
-$0.37-1.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.18% | 20.59% | 26.72% | 33.41% | 28.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.18% | 20.59% | 26.72% | 33.41% | 28.96% |
| Cost of Revenue | 10.84% | 11.97% | 8.16% | 8.67% | 11.73% |
| Gross Profit | 13.49% | 8.52% | 29.33% | 32.02% | 17.12% |
| SG&A Expenses | 8.72% | 8.55% | 8.43% | 6.21% | 3.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.22% | 10.95% | 8.24% | 7.92% | 9.22% |
| Operating Income | 0.19% | -1.55% | 7.97% | 11.52% | 5.83% |
| Income Before Tax | -0.71% | -2.68% | 9.72% | 11.16% | 6.81% |
| Income Tax Expenses | 100.00% | 268.46% | 269.29% | 253.08% | 209.59% |
| Earnings from Continuing Operations | -1.05% | -3.70% | 8.95% | 10.43% | 6.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.05% | -3.70% | 8.95% | 10.43% | 6.20% |
| EBIT | 0.19% | -1.55% | 7.97% | 11.52% | 5.83% |
| EBITDA | 0.00% | -1.44% | 9.02% | 13.32% | 7.95% |
| EPS Basic | 7.95% | 8.12% | 24.20% | 26.75% | 23.95% |
| Normalized Basic EPS | 8.29% | 9.46% | 24.84% | 28.34% | 24.41% |
| EPS Diluted | 7.95% | 8.12% | 24.20% | 26.75% | 23.95% |
| Normalized Diluted EPS | 8.29% | 9.46% | 24.84% | 28.34% | 24.41% |
| Average Basic Shares Outstanding | 8.94% | 12.29% | 19.24% | 21.46% | 23.12% |
| Average Diluted Shares Outstanding | 8.94% | 12.29% | 19.24% | 21.46% | 23.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |